Kalvista Pharmaceuticals Inc reports results for the quarter ended in July - Earnings Summary

Kalvista Pharmaceuticals

07/09/2023 12:06

* Kalvista Pharmaceuticals Inc  KALV.OQ  reported a
quarterly
adjusted loss of 74 cents​​ per share for the quarter ended in
July. The mean expectation of five analysts for the quarter was
for a loss of 86 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kalvista Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 74 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kalvista Pharmaceuticals Inc shares had risen by 19.7%
this
quarter and gained 59.4% so far this year.
    * The company reported a quarterly loss of $25.32 million.
    * Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $20.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
September 7 at 11:06 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jul. 31 2023      -0.86          -0.74          Beat
 Apr. 30 2023      -0.94          -0.77          Beat
 Jan. 31 2023      -0.98          -0.75          Beat
 Oct. 31 2022      -1.06          -0.90          Beat